List of Steglatro drug patents
Steglatro is owned by Merck Sharp Dohme.
Steglatro contains Ertugliflozin.
Steglatro has a total of 1 drug patent out of which 0 drug patents have expired.
Steglatro was authorised for market use on 19 December, 2017.
Steglatro is available in tablet;oral dosage forms.
Steglatro can be used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.
The generics of Steglatro are possible to be released after 13 July, 2030.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8080580 | MERCK SHARP DOHME | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives |
Jul, 2030
(7 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| M (M) | Sep 17, 2024 |
Drugs and Companies using ERTUGLIFLOZIN ingredient
Market Authorisation Date: 19 December, 2017
Treatment: An adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes
Dosage: TABLET;ORAL
STEGLATRO family patents
3
United States
2
China
2
Korea, Republic of
2
Hong Kong
2
Israel
1
Portugal
1
El Salvador
1
Malaysia
1
Uruguay
1
Panama
1
Spain
1
Brazil
1
Croatia
1
Costa Rica
1
Colombia
1
IB
1
New Zealand
1
AP
1
Dominican Republic
1
Norway
1
Argentina
1
Mexico
1
Austria
1
Morocco
1
Peru
1
Taiwan, Province of China
1
Honduras
1
Tunisia
1
EA
1
Nicaragua
1
South Africa
1
Lithuania
1
Canada
1
Japan
1
Cyprus
1
Slovenia
1
Hungary
1
ME
1
Ukraine
1
Cuba
1
Poland
1
Georgia
1
Chile
1
Australia
1
RS
1
Ecuador
1
Denmark
1
Netherlands
1
European Union
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic